Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Corcept TherapeuticsCORT +2.61%85 FCF Margin % is 12.11% as of Jun. 2026, which is 64% below its 10-year median of 33.93. GuruFocus rates CORT with a GF Score™ of 85/100 and a GF Value™ of $68.28 (Significantly Overvalued). The stock has 9 warning signs investors should review. Among 954 Biotechnology companies, Corcept Therapeutics ranks better than 85.43% on this metric.
The historical data trend for Corcept Therapeutics's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Corcept Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Corcept Therapeutics FCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Corcept Therapeutics's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Corcept Therapeutics's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Corcept Therapeutics (CORT) has a FCF Margin % of 12.11% as of Jun. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Corcept Therapeutics and its competitors. This is 64% below median its historical median of 33.93. Over the past decade, Corcept Therapeutics' FCF Margin % has ranged from 12.87 to 45.92. According to the industry distribution chart, Corcept Therapeutics ranks #139 out of 954 companies in the Biotechnology industry, placing it in the top 14.6%.
Is Corcept Therapeutics' FCF Margin % too high?
Corcept Therapeutics' current FCF Margin % of 12.11% is 64% below median its 10-year median of 33.93. Over the past 10 years, this metric has ranged from a low of 12.87 to a high of 45.92. Based on the distribution chart, Corcept Therapeutics ranks #139 out of 954 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Corcept Therapeutics has a GF Score™ of 85/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Corcept Therapeutics' FCF Margin % compare to APGE and KRYS?
According to the Biotechnology industry distribution chart, Corcept Therapeutics ranks #139 out of 954 companies for FCF Margin %. This places Corcept Therapeutics in the top 15% of its industry — outperforming the majority of peers. Historically, Corcept Therapeutics' own FCF Margin % has ranged from 12.87 to 45.92 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Corcept Therapeutics and its competitors. Corcept Therapeutics's current FCF Margin % is 12.11%, which is 64% below median its own 10-year median of 33.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Corcept Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Corcept Therapeutics (CORT) is currently considered Significantly Overvalued. The stock's GF Value™ is $68.28, compared to a current price of $110.77 — trading 62.2% above its estimated fair value. The current FCF Margin % is 12.11%, which is 64% below median its 10-year median of 33.93. Corcept Therapeutics' overall GF Score™ is 85/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Corcept Therapeutics (CORT), the current FCF Margin % is 12.11% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Corcept Therapeutics (CORT) Overvalued in 2026?
Based on GuruFocus' analysis, Corcept Therapeutics stock appears to be overvalued.
The current stock price of $110.77 is trading 62.2% above its estimated GF Value™ of $68.28.
GuruFocus considers Corcept Therapeutics to be Significantly Overvalued.
Key valuation signals for CORT:
FCF Margin %: 12.11% (64% below median its 10-year median of 33.93)
GF Value™: $68.28 vs. price of $110.77 (62.2% above fair value)
No single metric tells the full story. See the CORT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.
85GF Score
Get the complete analysis for CORT
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CORT has been successfully added to your 
